hrp0097fc11.2 | GH and IGFs | ESPE2023

Clinical characteristics of heterozygous ACAN gene variants and longer-term response to growth hormone treatment: real-world data

Renes Judith , Reedijk Ardine , Losekoot Monique , Kant Sarina , van der Steen Manouk , van der Kaay Danielle , Hokken-Koelega Anita , van Duyvenvoorde Hermine , de Bruin Christiaan

Background: Heterozygous pathogenic variants in the ACAN gene underlie disproportionate short stature with characteristically accelerated bone age (BA) maturation and/or osteochondritis dissecans (OD)/early-onset osteoarthritis (OA).Objective: To describe the phenotypic spectrum and assess the response and safety of growth hormone (GH) treatment in children with a heterozygous pathogenic ACAN variant.</...

hrp0098fc7.1 | GH and IGFs | ESPE2024

Clinical characteristics and response to growth hormone treatment in 27 children and adolescents with pathogenic NPR2 variants

S. Renes Judith , M.J. Reedijk Ardine , M.C. Hendriks Yvonne , Bakker Boudewijn , M. Boot Annemieke , A. van Setten Petra , C.M. van der Kaay Daniëlle , C.S. Hokken-Koelega Anita , Losekoot Monique , A. van Duyvenvoorde Hermine , de Bruin Christiaan

Background: The NPR2 gene plays a critical role in the human growth plate. Pathogenic NPR2 variants can result in varying degrees of short stature. The majority of subjects have no specific clinical findings and are likely classified as idiopathic short stature.Objective: To describe the phenotypic spectrum, analyze genotype-phenotype correlations and assess the response and safety of growth hormone (GH...

hrp0098rfc7.5 | GH and IGFs | ESPE2024

Health-related quality of life at mid-puberty in adolescents with idiopathic isolated growth hormone deficiency

Vliegenthart Joeri , van Busschbach Jan , Maarten Wit Jan , Bakker Boudewijn , Boot Annemieke , de Bruin Christiaan , Finken Martijn , van der Heyden Josine , Hokken-Koelega Anita , van der Kamp Hetty , de Kort Sandra , van Mil Edgar , Reedijk Ardine , Sas Theo , Schott Nina , van Setten Petra , Straetemans Saartje , van Tellingen Vera , Touwslager Bob , van Trotsenburg Paul , Voorhoeve Paul , van der Kaay Danielle

Introduction: Health related Quality of Life (QoL) outcome is used as an argument when continuation or stopping growth hormone (GH) treatment is considered in patients with idiopathic isolated growth hormone deficiency (IIGHD) who tested GH sufficient in mid-puberty (inclusion moment for this study).Aim: To assess potential differences in QoL between patients with IIGHD who discontinued treatment and those who continued ...